SNMMI launches AI-powered trial finder for radiopharmaceuticals
The Society of Nuclear Medicine and Molecular Imaging has unveiled a comprehensive digital platform designed to streamline patient access to radiopharmaceutical clinical trials. The Global Radiopharmaceutical Trial Finder utilises artificial intelligence to match patients, physicians, and researchers with relevant studies across multiple international registries, addressing critical gaps in clinical trial participation rates.
Radiopharmaceuticals
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has launched an artificial intelligence-driven platform aimed at enhancing patient access to radiopharmaceutical clinical trials worldwide. The Global Radiopharmaceutical Trial Finder, developed in partnership with Ancora.ai, represents a targeted response to persistently low clinical trial participation rates in nuclear medicine.
Addressing participation barriers in nuclear medicine trials
Clinical trial participation remains critically low despite patient willingness to engage with experimental treatments. Data from the National Institutes of Health indicates that whilst 84% of patients would consider participating in a clinical trial if recommended by their physician, only 3% to 5% of eligible adult cancer patients actually enrol in studies.
The platform addresses these participation barriers by providing real-time access to global trials data, refreshed every 24 hours from ClinicalTrials.gov and three additional international registries. The system operates without storing or selling personal information, maintaining patient privacy whilst facilitating trial discovery.
Tailored matching system for multiple user groups
The Trial Finder employs a stratified approach to serve different user requirements. Patients begin by selecting their medical condition and postal code, before responding to specific questions regarding disease stage, prior treatments, and other eligibility criteria. The system subsequently generates a tailored list of potentially suitable trials, including match strength indicators and geographical proximity data.
Physicians utilise the same interface to identify appropriate trial opportunities for their patients, whilst researchers can search thousands of radiopharmaceutical trials using parameters such as trial phase, radionuclide type, and therapeutic targets. The platform’s Quick Charts feature provides real-time analytical breakdowns of trial types, locations, sponsors, and other relevant criteria.
Expanding access to nuclear medicine innovations
Radiopharmaceutical clinical trials are essential for developing new diagnostic and therapeutic approaches in nuclear medicine, with potential applications in cancer diagnosis, treatment, and in some cases, cure. The platform aims to democratise access to these potentially life-saving interventions by eliminating traditional barriers to trial discovery and participation.
The Global Radiopharmaceutical Trial Finder is hosted on the SNMMI website and provides immediate access to comprehensive trial information for patients, physicians, and researchers globally.
- For more information, visit: snmmi.org/TrialFinder
